Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 6/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PDE6D | O43924 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4524718 | 0.92 | KIF11 (0.48) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 | |
| SCHEMBL5724300 | 0.81 | KIF11 (0.55) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 | |
| SCHEMBL5751997 | 0.80 | KIF11 (0.45) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 | |
| SCHEMBL4518988 | 0.79 | KIF11 (0.51) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 | |
| SCHEMBL4523383 | 0.78 | KIF11 (0.71) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 | |
| SCHEMBL4522589 | 0.78 | KIF11 (0.48) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 | |
| SCHEMBL4523385 | 0.78 | KIF11 (0.58) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 | |
| SCHEMBL6454042 | 0.78 | KIF11 (0.62) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 | |
| SCHEMBL4513091 | 0.77 | KIF11 (0.48) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 | |
| SCHEMBL5517277 | 0.76 | KIF11 (0.49) | KIF11CYP3A4MAP1LC3BCYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528137-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7214800-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1553931-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060094735-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2006-05-04 | — | — | US | disclosed |
| EP-1553931-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20040077668-A1 | Compounds, compositins, and methods | CYTOKINETICS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2003097053-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077668-A1 | Compounds, compositins, and methods | CEP170, PSAP, PACSIN2 | KIF11 1233/4885CYP3A4 4624/4885MAP1LC3B 1225/4885 |
| US-20060094735-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | KIF11 562/4885CYP3A4 4722/4885MAP1LC3B 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.